- Home
- ONEG vs PASG Comparison
ONEG vs PASG Comparison
Compare ONEG & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | PASG |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 27 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 14.8M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONEG | PASG |
|---|---|---|
| Price | $1.04 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 27.0K | 21.1K |
| Earning Date | 01-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $3.29 |
| 52 Week High | $14.95 | $20.00 |
Technical Indicators
Market Signals| Indicator | ONEG | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 65.15 |
| Support Level | $1.00 | $4.94 |
| Resistance Level | $1.06 | $5.92 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 65.87 | 75.94 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction projects include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.